We are live on ! Find out more
FP

Flagship Pioneering Portfolio holdings

AUM $1.16B
1-Year Est. Return 67.93%
This Fund
S&P 500
This Quarter Est. Return
+34.41%
1 Year Est. Return
+67.93%
3 Year Est. Return
-39.17%
5 Year Est. Return
-45.89%
10 Year Est. Return
AUM
$2.13B
AUM Growth
+$345M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
8
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MRNA icon
1
Moderna
MRNA
$21.5B
$1.52B 71.42%
50,871,524
RUBY
2
DELISTED
Rubius Therapeutics, Inc
RUBY
$170M 7.99%
38,296,526
DNLI icon
3
Denali Therapeutics
DNLI
$3.67B
$140M 6.55%
7,980,263
KLDO
4
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$107M 5%
17,360,710
MCRB icon
5
Seres Therapeutics
MCRB
$48.1M
$77M 3.61%
1,078,588
EVLO
6
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$68.6M 3.21%
911,670
AXLA
7
DELISTED
Axcella Health Inc. Common Stock
AXLA
$29.9M 1.4%
349,937
SYRS
8
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$17.4M 0.82%
293,849

Similar funds

Flagship Pioneering's Q1 2020 Portfolio in Review

As of Q1 2020, Flagship Pioneering held 8 positions worth $2.13B, up 19% from $1.79B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q1 2020: portfolio turnover was 0%. Flagship Pioneering opened no new positions and made no exits, leaving the 8-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Flagship Pioneering's ten largest holdings make up 100% of its $2.13B portfolio in Q1 2020.
  • Flagship Pioneering opened 0 new positions and closed 0 in Q1 2020.
  • Flagship Pioneering's portfolio value rose 19% quarter-over-quarter to $2.13B.

Based on Flagship Pioneering's 13F filing for Q1 2020, filed 14 May 2020.